Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Influenza-related hospitalisation and death in Australians aged 50 years and older

Anthony T. Newall, James G. Wood, C. Raina MacIntyre

The School of Public Health, The University of Sydney, NSW, Australia
The School of Public Health and Community Medicine, University of New South Wales, NSW, Australia
National Centre for Immunisation Research and Surveillance (NCIRS) of Vaccine Preventable Diseases, The Children’s Hospital at Westmead, and The University of Sydney, Locked Bag 4001, NSW 2145, Australia

Received 2 August 2007; received in revised form 22 January 2008; accepted 30 January 2008
Available online 15 February 2008

KEYWORDS
Influenza; Regression analysis; Mortality; Hospitalisation

Summary
Estimating the true burden of influenza is problematic because relatively few hospitalisations or deaths are specifically coded as influenza related. Statistical regression techniques using influenza and respiratory syncytial virus surveillance data were used to estimate the number of excess hospitalisations and deaths attributable to influenza. Several International Classification of Diseases 10th Revision (ICD-10) groupings were used for both hospitalisation and mortality estimates, including influenza and pneumonia, other respiratory disorders, and circulatory disorders. For Australians aged 50–64 years, the annual excess hospitalisations attributable to influenza were 33.3 (95%CI: 23.2–43.4) per 100,000 for influenza and pneumonia and 57.6 (95%CI: 32.5–82.8) per 100,000 for other respiratory disorders. For Australians aged ≥65 years, the annual excess hospitalisations attributable to influenza were 157.4 (95%CI: 108.4–206.5) per 100,000 for influenza and pneumonia and 282.0 (95%CI: 183.7–380.3) per 100,000 for other respiratory disorders. The annual excess all-cause mortality attributable to influenza was 6.4 (95%CI: 2.6–10.2) per 100,000, for Australians aged 50–64 years and those aged ≥65 years, respectively. In the age-group ≥65 years, a significant association was found between influenza activity and circulatory mortality. We conclude that influenza is responsible for a substantial amount of mortality and morbidity, over and above that which is directly diagnosed as influenza in Australians aged ≥50 years.

© 2008 Elsevier Ltd. All rights reserved.

DOI of original article: 10.1016/j.vaccine.2008.01.050.
* Corresponding author. Tel.: +61 2 9845 1433; fax: +61 2 9845 1418.
E-mail addresses: AnthonyN@chw.edu.au, tony.newall@hotmail.com (A.T. Newall), jamesw5@chw.edu.au (J.G. Wood), RainaM@chw.edu.au (C.R. MacIntyre).

Introduction

In Australia, as internationally, relatively few hospitalisations or deaths are specifically coded as influenza related [1,2]. While evidence suggests that influenza infection is associated with a variety of respiratory [3] and circulatory conditions [4], laboratory diagnosis of influenza is uncommon, and complications resulting from influenza infection are unlikely to be attributed to influenza. Despite a lack
of coded cases, a rise in mortality is observed within the influenza season, particularly in years with high influenza incidence [1,2]. Estimation of the “excess” disease burden due to influenza can be statistically complex, but is important for assessing the potential benefits and cost-effectiveness of vaccination programs.

Currently, the Australian government only funds universal influenza vaccine for adults aged 65 years and above [5], yet over one quarter of Australians aged 50—64 years are considered to be at high-risk for complications arising from influenza infection [5]. The vaccination rate in this age-group is 33%, with less than half of those at high-risk being immunised [5]. Therefore, assessing the disease burden in this age-group is of particular interest both in Australia and internationally. Recent cost-effectiveness studies of universal influenza vaccination in those aged 50—64 years in Europe and the US have generally reported favourable results [6—8]. Various statistical techniques have been used to estimate the excess disease burden that is attributable to influenza. One of the simplest methods involves calculating the excess disease burden which occurs during periods of influenza activity over that occurring in baseline periods (i.e. periods when influenza is not circulating) [3,9,10]. However, results derived from this method may be inaccurate if other seasonally variable causes of disease are not considered. More complex statistical techniques are required to account for other seasonal variables and to assess the proportion of the excess disease burden that is attributable only to influenza. Two commonly used methods are Serfling-type models [11—14] and Poisson regression models [15—17]. While there is debate around strengths and weakness of the various statistical approaches [18—21], these two approaches can produce similar estimates when applied to the same time-period and population [19].

In Australia, the most recent estimates of excess influenza mortality were published more than 20 years ago [1,2], prior to the availability of national laboratory surveillance data. To our knowledge, no Australian estimates of influenza-attributable hospitalisations have been published. This study used this surveillance data as covariates in multiple regression models to estimate the excess hospitalisations (July 1998—June 2005) and excess deaths (January 1997—October 2004) attributable to influenza in Australians aged ≥50 years.

Method

We utilised data from the National Hospital Morbidity Database (NHMD) for the period July 1998—June 2005 and data from the National Mortality Database (NMD) for the period January 1997—October 2004. The NHMD contains administrative, demographic and clinical information about all patients admitted to public and private hospitals in Australia. The NMD contains cause of death information for all registered deaths in Australia. Hospitalisation and mortality data were supplied by the Australian Institute of Health and Welfare (AIHW).

All data supplied by the AIHW were categorised using the International Classification of Diseases 10th Revision (ICD-10) [22]. For both hospitalisation and mortality estimates a number of ICD-10 groupings were examined: influenza and pneumonia (ICD J10-18), other respiratory disorders (ICD J, excluding J10-18), circulatory disorders (ICD I), and for mortality, all-cause death was also examined. The analysis was restricted to records in which these ICD codes appeared as the “principal” cause of hospitalisation or the “underlying” cause of death. Monthly hospitalisation and mortality data were utilised. Population estimates were obtained from the Australian Bureau of Statistics (ABS) [23].

Influenza (A and B) and respiratory syncytial virus (RSV) activity were obtained from the Laboratory Virology and Serology Reporting Scheme (LabVISE). LabVISE is a national system of sentinel laboratories which analyses specimens all year round. In 2005, there were 11 participating laboratories from all states and territories except Western Australia and the Northern Territory [24]. LabVISE data were supplied from January 1997 to June 2005. In Australia RSV activity has been known to overlap with influenza activity (Fig. 1). Internationally, previous models have shown that RSV (like influenza), while often undiagnosed, is responsible for significant mortality [15]. As in previous models estimating influenza disease burden [15—17] RSV activity was included as a covariate in the model. By including RSV activity in the model, the deaths (or hospitalisations) attributable to RSV are accounted for, and should not be confounded with deaths from influenza.

Poisson and negative-binomial regression models are basic models for count data analysis. We used a generalised linear model (GLM) procedure, assuming Poisson-distributed errors with the response variable (hospitalisations or deaths) assumed to be linear and additive in the covariates [20]. We tested for over-dispersion of errors, and when this was observed (in all models except those for mortality 50—64 years), the models were run again with negative-binomial error distributions. A negative-binomial model allows for the variance to be greater than the mean, and is therefore more appropriate in cases of over-dispersion. In the final models (for hospitalisation and mortality), the values of Pearson chi-squared and deviance divided by the degrees of freedom were not significantly larger than one suggesting a good fit to the data.

The regression model was applied to each of the disease categories in the study. The model used was as follows:

\[ Y(t) = \alpha + \beta_1[A](t) + \beta_2[B](t) + \beta_3[RSV](t) + \beta_4\cos(2\pi t/12) + \beta_5\sin(2\pi t/12) + \beta_6[\text{population}](t) + \text{Error}(t) \]

where \( Y(t) \) is the number of deaths or hospitalisations predicted by the model in a month for a specific age-group, \([A](t)\), \([B](t)\) and \([RSV](t)\) are laboratory specimen counts for a given month (for influenza A, influenza B and RSV, respectively), \(\sin(2\pi t/12)\) and \(\cos(2\pi t/12)\) are proxy variables reflecting annual fluctuations that are independent of influenza and RSV, and \([\text{population}](t)\) represents the age-specific population size, to account for changing demography. Values for the parameters \(\alpha\) and \(\beta_1-\beta_6\) were then obtained by running the regression model. The number of hospitalisations or deaths attributable to influenza was calculated by the difference between the number predicted by the model and the number predicted by the model when the influenza laboratory reports were set to 0. All statistical analysis was conducted in SAS statistical software (V 9.1 SAS Institute Inc., Cary, NC).
Results

The fit of the model can be assessed by comparing the numbers of hospitalisations or deaths predicted using the model and the actual numbers observed in the data set (Fig. 2).

For Australians aged 50–64 years, the annual excess hospitalisations attributable to influenza were 33.3 (95%CI: 23.2–43.4) per 100,000 for influenza and pneumonia and 57.6 (95%CI: 32.5–82.8) per 100,000 for other respiratory disorders (Table 1). For Australians aged ≥65 years, the annual excess hospitalisations attributable to influenza were 157.4 (95%CI: 108.4–206.5) per 100,000 for influenza and pneumonia and 282.0 (95%CI: 183.7–380.3) per 100,000 for other respiratory disorders.

The annual excess all-cause mortality attributable to influenza was 6.4 (95%CI: 2.6–10.2) per 100,000 and 116.4 (95%CI: 71.3–161.5) per 100,000, for Australians aged 50–64 years and those aged ≥65 years, respectively (Table 2). Influenza was found to be associated with 1.3% of all deaths in Australians aged 50–64 years and 2.8% of all deaths in those aged ≥65 years.

For those aged 50–64 years, no significant association was found between influenza activity and circulatory hospitalisations or circulatory mortality in the model. Similarly, no association was found between influenza activity and circulatory hospitalisations in those aged ≥65 years. However, in Australians aged ≥65 years, influenza-related circulatory mortality accounted for approximately 1200 deaths annually (Table 2).

Discussion

Estimates from the model indicate that on average over 3000 deaths were attributable to influenza each year in Australians aged ≥50 years. The majority of these occurred in those aged ≥65 years, however in those aged 50–64 years over 196 deaths were attributed to influenza. We found that influenza was responsible for more than 13,500 hospitalisations each year in those aged ≥50 years, with approximately a fifth of these occurring in those aged 50–64 years.

Over the same period as this study the annual mean number of deaths recorded as being due to laboratory-confirmed influenza (ICD-10, J10) in Australians aged over 50 years was approximately one per year. There were another 75 deaths
per year coded as influenza where influenza virus was not confirmed (J11). The results of this study suggest that these coded deaths represent a significant underestimation of the true influenza disease burden.

The two previous Australian estimates of excess influenza mortality were published more than 20 years ago [1,2]. De Ravin and Gerrard estimated that for every death coded as influenza related there were another 8.2 deaths attributable to influenza, equating to an average of 2128 annually for all-ages over the period 1968–1981 [1]. Scagg examined the increase in deaths during the 1974 epidemic and found a 6% increase in all-cause deaths [2].

In general, Australian estimates for mortality were lower than rates estimated (using similar models) in other countries, whereas estimates of hospitalisations were similar to the US but higher than those estimated for other countries [15–17]. However, there was variation in these results by age-group and category of hospitalisation or mortality (Table 3). For example for mortality in those aged 50–64 years, rates estimated for the US (all-cause death: 12.5 per 100,000 [15]) were approximately double the Australian estimates (all-cause death: 6.4 per 100,000), whereas in those aged ≥65 years rates of all-cause mortality for the US were 132.5 per 100,000 compared to 116.4 per 100,000 for Australia [15].

The differences in influenza-attributable disease between countries could be the result of several factors. They could reflect differences in the severity of influenza epidemics, climatic factors, vaccination coverage, population demographics, the time-period considered, or differences in access and utilisation of health care. However, they could also be the result of methodological differences in the models used, for example, Thompson et al. utilised weekly virological data, whereas this study utilised monthly data [15]. While weekly data may provide a more powerful method of estimating influenza-attributable disease, it also increases issues associated with time delays between influenza activity and influenza mortality. Adjustment for time delays is complicated by the different influenza mortality pathways. The use of monthly data (rather than weekly data) should reduce the need to account for time delays.

In those aged ≥65 years, influenza was responsible for more circulatory deaths than respiratory deaths. However, no significant association between influenza and circulatory mortality was found in the model for those aged 50–64 years. While several studies have found circulatory mortality associated with influenza in the 50–64 years age-group [17,25], many studies have utilised a combined ‘‘respiratory and circulatory’’ category making it difficult to determine

| Table 1 | Estimated excess hospitalisations attributed to influenza in Australians aged 50–64 years and those aged ≥65 years |
|---------|-------------------------------------------------------------------------------------------------------------|
| 50–64 years | 0.123 (0.086 to 0.161) | 1057.7 (737.1 to 1378.3) | 33.3 (23.2 to 43.4) |
| ≥65 years | 0.124 (0.086 to 0.163) | 3894.5 (2681.3 to 5107.7) | 157.4 (108.4 to 206.5) |

| Table 2 | Estimated excess mortality attributed to influenza in Australians aged 50–64 years and those aged ≥65 years |
|---------|-------------------------------------------------------------------------------------------------------------|
| 50–64 years | 0.188 (0.083 to 0.292) | 19.6 (8.7 to 30.4) | 0.6 (0.3 to 1.0) |
| ≥65 years | 0.168 (0.123 to 0.212) | 425.8 (311.7 to 540.0) | 17.6 (12.9 to 22.3) |
### Table 3 Comparison of influenza-attributable hospitalisation and mortality between countries

| Study, country, years       | Hospitalisation (rate per 100,000) | Mortality (rate per 100,000) |
|----------------------------|------------------------------------|-----------------------------|
|                            | 50—64 years                        | 50—64 years                 |
|                            | ≥65 years                          | ≥65 years                   |
|                            | Influenza/ pneumonia                | Respiratory/ circulatory    | Influenza/ pneumonia                | Respiratory/ circulatory    | All-cause                   |
|                            |                                    |                             | Influenza/ pneumonia                | Respiratory/ circulatory    |                             | Influenza/ pneumonia                | Respiratory/ circulatory    | All-cause                   |
| Newall *Australia*, 1998—2005*, 1997—2004* | 33.3                              | 90.9c                       | 157.4                               | 439.5c                       | 0.6                         | 2.7c                        | 6.4                        | 17.6                         | 91.3                        | 116.4                       |
| Thompson [16] *US*, 1979—2001    | 37.9                              | 83.8                        | 205.0                               | 445.0                        | —                           | —                          | —                          | —                            | —                            | —                            |
| Scuffham [28] *Switzerland*, 1987—1997 | 44.2d                            | 65.6c,d                      | 63.0                                | 110.4c                       | —                           | —                          | —                          | —                            | —                            | —                            |
| Pitman [25] *UK*, 1996—2003a, 1990—1999b | —                                | 19.6c,f                      | —                                   | 136.9c                       | —                           | 8.2f                       | —                          | —                            | 176.6                       | —                            |
| Thompson [15] *US*, 1990—1999     | —                                 | —                           | —                                   | —                            | 1.3                         | 7.5                        | 12.5                       | 22.1                         | 98.3                        | 132.5                       |
| Wong [17] *Hong Kong*, 1996—1999  | —                                 | —                           | —                                   | —                            | 0.8g                        | 7.3g                       | 11.8g                      | 39.3                         | 102.0                       | 136.1                       |

* Primary hospitalisation.

a Hospitalisation.
b Mortality.
c Respiratory only.
d 51—65 years.
e Rates are approximated using the 'bacteria included' model [25].
f 45—64 years.
g 40—64 years.
the influenza-related circulatory disease burden [15,26,27].
No significant association between influenza activity and
circulatory hospitalisations was found in either age-group.
The lack of association with circulatory hospitalisation is
consistent with data from other studies [4]. One hypot-
thesis for this lack of association is that influenza infection
leads predominantly to rapid onset of circulatory disease
resulting in sudden death in the community, and is thus
not reflected in the circulatory hospitalisation statistics
[4].

The model utilised in this study assumes that vari-
ation in influenza laboratory reports accurately reflect
patterns of circulation in the population of interest. How-
ever, there are several limitations in the laboratory data
used. Firstly, variation in laboratory testing patterns in
Australia may not be consistent over time or place. This vari-
ation could result in an ascertainment bias, due to variation
in the number of tests ordered. Unfortunately, denomina-
tor data for all tests of respiratory viruses is not available
in Australia at present. Secondly, due to small numbers
of laboratory reports, all-age influenza activity was used,
rather than age-specific laboratory reports. Other causes
of respiratory infection (such as rhinovirus, entrovirus,
coronavirus, adenovirus or parainfluenza virus) may also
peak annually, and by disregarding these agents, the
influenza-related disease burden could be overestimated.
However, proxy seasonal variables were used in the model
to account for annual fluctuations that were independent
of influenza and RSV. Without these proxy variables signifi-
cantly more deaths and hospitalisations were attributable
to influenza.

We conclude that influenza is responsible for over 13,500
hospitalisations and over 3000 deaths in Australians aged
≥50 years. The majority of the disease burden occurs in
the elderly. However, the disease burden attributable to
influenza in those aged 50—64 years suggests that a sig-
nificant reduction in hospitalisation and mortality may be
achieved through an effective influenza vaccination program
targeted at this age-group.

Acknowledgements

AN is funded by a Public Health Postgraduate Scholarship
(402920) from the National Health and Medical Research
Council (NHMRC) of Australia, and by a GlaxoSmithKline Aus-
tralia Support Grant. We thank the Australian Institute of
Health and Welfare (AIHW) for provision of data. The authors
wish to thank Professor Paul Scuffham and Dr Heath Kelly
for their assistance in preparation of this manuscript.
The project was partially funded by a grant from the Influenza
Specialist Group.

References

[1] De Ravin JW, Gerrard PN. The effect of influenza on Australian
mortality. Ann Trans Aust Inst Act 1984;471—9.
[2] Scagg R. Effect of influenza epidemics on Australian mortality.
Med J Aust 1985;142(2):98—102.
[3] Fleming DM. The contribution of influenza to combined acute
respiratory infections, hospital admissions, and deaths in win-
ter. Commun Dis Public Health 2000;3(1):32—8.
[4] Fleming DM, Cross KW, Pannell RS. Influenza and its relation-
tship to circulatory disorders. Epidemiol Infect 2005;133(2):
255—62.
[5] Australian Institute of Health and Welfare. 2004 Adult vaccina-
tion survey: summary results. Canberra: AIHW & DoHa; 2005.
[6] Abalos R, Chancellor J, Martin M, Wutzler P, Carrat P, Gas-
parini R, et al. The cost-effectiveness of influenza vaccination for
people aged 50 to 64 years: an international model. Value
Health 2007;10(2):98—116.
[7] Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman
MJ. Influenza vaccination health impact and cost effectiveness
among adults aged 50 to 64 and 65 and older. Am J Prev Med
2006;31(1):72—9.
[8] Turner DA, Waitoo AJ, Cooper NJ, Sutton AJ, Abrams KR,
Nicholson KG. The cost-effectiveness of influenza vacci-
nation of healthy adults 50—64 years of age. Vaccine
2006;24(7):1035—43.
[9] Fleming DM, Pannell RS, Cross KW. Mortality in children from
influenza and respiratory syncytial virus. J Epidemiol Commu-

nity Health 2005;59(7):586—90.
[10] Neuzil KM, Reed GW, Mitchell Jr EF, Griffin MR. Influenza-
associated morbidity and mortality in young and middle-aged
women. JAMA 1999;281(10):901—7.
[11] Serfling RE. Methods for current statistical analysis of
excess pneumonia-influenza deaths. Public Health Rep
1963;78:494—506.
[12] Simonsen L, Clarke MJ, Williamson GD, Straw DP, Arden
NH, Schonberger LB. The impact of influenza epidemics on
mortality: introducing a severity index. Am J Public Health
1997;87(12):1944—50.
[13] Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact
of influenza epidemics on hospitalizations. J Infect Dis
2000;181(3):831—7.
[14] Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor
RJ, Miller MA. Impact of influenza vaccination on seasonal
mortality in the US elderly population. Arch Intern Med
2005;165(3):265—72.
[15] Thompson WW, Shlay DK, Weintraub E, Brammer L, Cox
NJ, Anderson LJ, et al. Mortality associated with influenza
and respiratory syncytial virus in the United States. JAMA
2003;289(2):179—86 [see comment].
[16] Thompson WW, Shlay DK, Weintraub E, Brammer L, Bridges
CB, Cox NJ, et al. Influenza-associated hospitalizations in the
United States. JAMA 2004;292(11):1333—40.
[17] Wong CM, Chan KP, Hedley AJ, Peiris JS. Influenza-associated
mortality in Hong Kong. Clin Infect Dis 2004;39(11):1611—7.
[18] Gienow WP, Couch RB. Estimating deaths due to influenza and
respiratory syncytial virus. JAMA 2003;289(19):2500—2 [com-
ment].
[19] Simonsen L, Blackwelder WC, Reichert TA, Miller MA. Estimat-
ing deaths due to influenza and respiratory syncytial virus.
JAMA 2003;289(19):2499—500 [comment].
[20] Gay NJ, Andrews NJ, Trotter CL, Edmunds WJ. Estimating
deaths due to influenza and respiratory syncytial virus. JAMA
2003;289(19):2499 [comment].
[21] Fleming DM, Cross KW, Watson JM, Verlander NQ. The cost-
effectiveness of influenza vaccination among adults aged 50 to
64 years: an international model. Value Health 2006;9(2):98—116.
[22] World Health Organization. International statistical classifica-
tion of diseases and related health problem, tenth revision.
Geneva: World Health Organization; 1992.
[23] Australian Bureau of Statistics. Australian demographic statis-
tics. Canberra: Australian Bureau of Statistics; 2005.
[24] Firestone SM, Barr G, Roche PW, Walker JC. Annual report of
the National Influenza Surveillance Scheme, 2005. Commun Dis
Intell 2006;30:189—200.
[25] Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;54(6):530–8.

[26] Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States—an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163(2):181–7.

[27] Li CK, Choi BC, Wong TW. Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 2006;120(6):517–24.

[28] Scuffham PA. Estimating influenza-related hospital admissions in older people from GP consultation data. Vaccine 2004;22(21–22):2853–62.